Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.

Biotechnology

Triplet Therapeutics

Nessan Bermingham

Jia Tay

W. George Lai

Peter Bialek

Alan J. Buckler

Eric Sullivan

Deborah Gouveia

Jeff Cerio

Irina Antonijevic

Amar Ghodasara

David Morrissey

Amy Lurier

Satya Kuchimanchi

Pei Ge

Brian Bettencourt

Eva Asp

The Leadership Team at Triplet Therapeutics is responsible for shaping the strategic direction of the company and overseeing its mission to develop innovative treatments for repeat expansion disorders. This team comprises executives from key functional areas, including research, clinical operations, finance, and legal, who collaborate to drive scientific advancements, ensure regulatory compliance, and manage talent acquisition. Their collective expertise and vision enable Triplet Therapeutics to leverage genetic insights and proprietary technologies effectively in the pursuit of groundbreaking therapies for patients.

Leadership Team

Research and Development

Corporate Functions

Leadership Team

About

Team members

Other teams at Triplet Therapeutics

Research and Development

Corporate Functions